Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, et al. Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat. 2016;156(2):405-6.

Pan J-, Sun Y, Jiang Y-, Bott AJ, Jaber N, Dou Z, et al. TRIM21 Ubiquitylates SQSTM1/p62 and Suppresses Protein Sequestration to Regulate Redox Homeostasis. Mol Cell. 2016;61(5):720-733.

Mohammed KH, Siddiqui MT, Cohen C. GATA3 immunohistochemical expression in invasive urothelial carcinoma. Urol Oncol. 2016;34(10):432.e9-432.e13.

Noy A, Lensing SY, Moore PC, Gupta N, Aboulafia D, Ambinder R, et al. Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium. Leuk Lymphoma. 2016;57(7):1731-4.

Nakanishi Y, Reina-Campos M, Nakanishi N, Llado V, Elmen L, Peterson S, et al. Control of Paneth Cell Fate, Intestinal Inflammation, and Tumorigenesis by PKCλ/ι. Cell Rep. 2016;16(12):3297-3310.

Inayat F, Law JK, Myers-Gurevitch PM, Seshan SV, Perlman AS. Minimal change disease: an unusual presentation of marginal zone MALT lymphoma. Clin Nephrol. 2016;85(3):184-8.

Ouseph MM, Kleinman ME, Wang QJ. Vision loss in juvenile neuronal ceroid lipofuscinosis (CLN3 disease). Ann N Y Acad Sci. 2016;1371(1):55-67.

Loda M. Challenging Roadblocks to Cancer Cure. Cancer Res. 2016;76(17):4924-30.

Totonchy J, Cesarman E. Does persistent HIV replication explain continued lymphoma incidence in the era of effective antiretroviral therapy? Curr Opin Virol. 2016;20:71-77.

Fader AN, Java J, Tenney M, Ricci S, Gunderson CC, Temkin SM, et al. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol. 2016;143(3):460-465.